摩通维持石药(1093.HK)“增持”评级目标价20港元
摩根大通发表研究报告称,石药(01093.HK)新药表现仍然被低估,管理层预计下半年仍有5-6只新仿制药获批,未来两年有约10只创新药达至第三阶段或注册评估阶段。该行维持其“增持”评级,以及目标价20港元不变。

该行指出,石药股价在公布业绩后上升,相信是因为其长远增长的可见性。虽然政府公布新的药物名册或对恩必普(NBP)带来担忧,但相信影响有限,预期今年整体盈利增长为25%,2020-21年为27%。该行虽然对欧来宁的表现预期较低,但调升对公司2019-21年收入预期6%-8%,以反映肿瘤科药物销售较预期强劲,和仿制药增长加快。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.